Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Toxicol Pathol ; 49(2): 286-295, 2021 02.
Article in English | MEDLINE | ID: mdl-32815455

ABSTRACT

Serelaxin is a recombinant human relaxin-2 intended for cardiovascular indications. Inhalation was chosen as alternative route to intravenous to allow daily administration for chronic applications and home treatment. A total of 4 short-term studies were conducted in rats and cynomolgus monkeys with inhaled formulation of serelaxin at dose up to 10 mg/kg/d. All rats and cynomolgus macaques receiving serelaxin were exposed to the test item. One rat and approximately 50% of macaques developed immunogenicity, which did not appear to affect exposure. No adverse effect on respiratory function or systemic changes was noted. Both species developed similar microscopic lesions characterized by eosinophilic cell infiltration around bronchi; however, in the rat, this was more pronounced and extended to a perivascular location. In addition, in the rat, serelaxin showed eosinophilic crystalline material associated with macrophages in the alveoli and bronchioles. In macaques, serelaxin induced minimal macrophage infiltrates in alveoli and perivascular/peribronchiolar mononuclear cell infiltrations. The minimal airway eosinophilic/mononuclear inflammatory cell infiltrations were considered to be nonadverse in macaques due to the minimal severity and the lack of any other alterations in the lung parenchyma. In the rat, the presence of eosinophilic crystalline material and macrophage response, characterized as precipitated test article, was considered adverse.


Subject(s)
Lung , Relaxin , Animals , Humans , Macaca fascicularis , Rats , Recombinant Proteins/toxicity , Relaxin/toxicity
2.
J Med Chem ; 59(16): 7544-60, 2016 08 25.
Article in English | MEDLINE | ID: mdl-27502541

ABSTRACT

Cancer Osaka thyroid (COT) kinase is an important regulator of pro-inflammatory cytokines in macrophages. Thus, pharmacologic inhibition of COT should be a valid approach to therapeutically intervene in the pathogenesis of macrophage-driven inflammatory diseases such as rheumatoid arthritis. We report the discovery and chemical optimization of a novel series of COT kinase inhibitors, with unprecedented nanomolar potency for the inhibition of TNFα. Pharmacological profiling in vivo revealed a high metabolism of these compounds in rats which was demonstrated to be predominantly attributed to aldehyde oxidase. Due to the very low activity of hepatic AO in the dog, the selected candidate 32 displayed significant blood exposure in dogs which resulted in a clear prevention of inflammation-driven lameness. Taken together, the described compounds both potently and selectively inhibit COT kinase in primary human cells and ameliorate inflammatory pathologies in vivo, supporting the notion that COT is an appropriate therapeutic target for inflammatory diseases.


Subject(s)
Drug Discovery , Imidazoles/pharmacology , MAP Kinase Kinase Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins/antagonists & inhibitors , Quinolines/pharmacology , Animals , Crystallography, X-Ray , Dogs , Dose-Response Relationship, Drug , Humans , Imidazoles/chemical synthesis , Imidazoles/chemistry , MAP Kinase Kinase Kinases/metabolism , Male , Models, Molecular , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Proto-Oncogene Proteins/metabolism , Quinolines/chemical synthesis , Quinolines/chemistry , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.
Clin Teach ; 9(3): 152-7, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22587313

ABSTRACT

BACKGROUND: Clinical reasoning is one of the most important skills that medical students need to develop. Our medical students learn clinical reasoning in small group discussion sessions and during their clinical attachments. We wanted to provide additional opportunities for them to develop these important skills. CONTEXT: Our undergraduate paediatric curriculum is based on 25 clinical presentations, and is delivered on the website myPaediatrics. We used simple show-and-hide case examples in each presentation to illustrate to students how to use the knowledge and skills they acquire to solve the clinical presentations. These are popular with students but provide little opportunity for interaction. INNOVATION: Based on two commonly available formats for the virtual patient, neither of which had fully met the specific needs of our undergraduate students, we developed hybrid software: evPaeds. Close collaboration with students and teachers ensured that evPaeds met the unique learning needs of undergraduate students. evPaeds incorporates the Paediatric Decision Tree, which encourages students to make decisions on investigations and management, with immediate feedback. Explicitly referring to the basic sciences in our virtual patients resulted in them being valuable to students in both the pre-clinical and clinical years. IMPLICATIONS: evPaeds has proven popular with students to practise and develop clinical reasoning, individually or in small group sessions.


Subject(s)
Curriculum , Decision Making , Education, Medical, Undergraduate/methods , Internet , Students, Medical , Teaching/methods , Decision Trees , Humans , Learning , Software , User-Computer Interface
5.
J Med Chem ; 54(19): 6888-904, 2011 Oct 13.
Article in English | MEDLINE | ID: mdl-21870878

ABSTRACT

A novel tertiary amine series of potent muscarinic M(3) receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M(3) receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.


Subject(s)
Azetidines/chemical synthesis , Bronchodilator Agents/chemical synthesis , Diphenylacetic Acids/chemical synthesis , Pulmonary Disease, Chronic Obstructive/drug therapy , Receptor, Muscarinic M3/antagonists & inhibitors , Administration, Inhalation , Animals , Azetidines/chemistry , Azetidines/pharmacology , Bronchodilator Agents/chemistry , Bronchodilator Agents/pharmacology , CHO Cells , Cell Line , Cell Membrane Permeability , Cricetinae , Cricetulus , Diphenylacetic Acids/chemistry , Diphenylacetic Acids/pharmacology , Dogs , Female , Guinea Pigs , Hepatocytes/metabolism , Humans , In Vitro Techniques , Kinetics , Male , Microsomes, Liver/metabolism , Muscle Relaxation/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiology , Radioligand Assay , Rats , Receptor, Muscarinic M3/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship , Trachea/drug effects , Trachea/physiology
6.
J Med Chem ; 53(18): 6640-52, 2010 Sep 23.
Article in English | MEDLINE | ID: mdl-20804199

ABSTRACT

A novel series of potent and selective sulfonamide derived ß(2)-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease. Analogues from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips. The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events. Compound 38 (PF-610355) is identified as a clinical candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans. Compound 38 is currently in advanced phase II clinical studies.


Subject(s)
Adrenergic beta-2 Receptor Agonists , Adrenergic beta-Agonists/chemical synthesis , Asthma/drug therapy , Benzeneacetamides/chemical synthesis , Pulmonary Disease, Chronic Obstructive/drug therapy , Sulfonamides/chemical synthesis , Administration, Inhalation , Adrenergic beta-Agonists/pharmacokinetics , Adrenergic beta-Agonists/pharmacology , Animals , Benzeneacetamides/pharmacokinetics , Benzeneacetamides/pharmacology , Bronchoconstriction/drug effects , CHO Cells , Cricetinae , Cricetulus , Crystallography, X-Ray , Dogs , Female , Guinea Pigs , Hepatocytes/metabolism , Humans , In Vitro Techniques , Liver/metabolism , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Models, Molecular , Molecular Structure , Muscle, Smooth/drug effects , Muscle, Smooth/physiopathology , Rats , Stereoisomerism , Sulfonamides/pharmacokinetics , Sulfonamides/pharmacology , Trachea/drug effects , Trachea/metabolism , Trachea/physiopathology
7.
Mutagenesis ; 24(5): 433-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19581339

ABSTRACT

We have developed the bioluminescent Salmonella reverse mutation assay as a tool for detecting mutagenicity applicable for high-throughput screening of new chemicals. In this study, we report the inter-laboratory evaluation of the assay using 10 model chemicals in five independent laboratories located in the USA (Groton, CT; Cambridge, MA and La Jolla, CA), Europe (Sandwich, Kent, UK) and Asia (Nagoya, Japan). The studies were performed in blinded fashion in all sites except for Groton and Cambridge laboratories. The chemicals were tested in at least three independent experiments using strains TA98-lux and TA100-lux in the presence and absence of metabolic activation. The results were statistically evaluated and compared to published results. Seven of the 10 compounds were positive in either TA98-lux and/or TA100-lux in the presence or absence of metabolic activation. The positive compound set included: nitrofurazone, 3-3'-dimethoxybenzidine, benzo[a]pyrene, 1,4-benzoquinone dioxime, 2-amino-5-nitrophenol, 2-bromo-4,6-dinitroaniline and busulfan. The remaining three compounds, namely, anthracene, crystal violet and benzyl chloride were negative in both Salmonella strains. Final results for individual compounds yielded 100% agreement among the laboratories and published data. Detailed comparison of all 40 individual test conditions yielded 93% (37 of 40) agreement among participating laboratories. We conclude that the bioluminescent Salmonella reverse mutation assay is a robust, accurate and economical higher throughput assay applicable for the mutagenicity screening of chemicals.


Subject(s)
Luminescent Measurements , Mutagens/toxicity , Mutation/drug effects , Mutation/genetics , Salmonella/drug effects , Salmonella/genetics , Laboratories , Mutagenicity Tests
8.
Toxicology ; 216(2-3): 168-80, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16168553

ABSTRACT

Buthionine sulphoximine (BSO; 1mM) resulted in the depletion of glutathione (GSH) in HepG2 cells to 17+/-1.5% within 24h. This was not associated with apoptotic or necrotic cell death over this time period. Use of a human (Phase 1) cDNA custom toxicology-array and a larger scale (>10,000 gene) Affymetrix U95Av2 array identified a total of 48 and 104 genes, respectively, with a statistically significant (and >1.5-fold) change in expression. A total of 64 differentially expressed genes (6 of which were confirmed by real-time polymerase chain reaction) were suggestive of protein kinase C (PKC) activation. Activation of PKC-alpha (but not betaI or delta) was demonstrated at 24 h through activity measurements and through Western blot analysis of membrane-associated PKC-alpha protein. Activation did not occur in the presence of additional gamma-glutamylcysteine to prevent GSH depletion. Activation of PKC-alpha by GSH-depletion may, at least in part, be mediated by thiol oxidation and may contribute to a survival signal. If sustained, the activation may be important in non-genotoxic carcinogenesis.


Subject(s)
Gene Expression Regulation, Enzymologic , Glutathione/deficiency , Glutathione/metabolism , Protein Kinase C-alpha/metabolism , Animals , Apoptosis/drug effects , Blotting, Western , Buthionine Sulfoximine/pharmacology , Carcinoma, Hepatocellular/enzymology , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Enzyme Activation/drug effects , Gene Expression Profiling/methods , Humans , L-Lactate Dehydrogenase/metabolism , Liver Neoplasms/enzymology , Liver Neoplasms/metabolism , Oligonucleotide Array Sequence Analysis , Phosphorylation/drug effects , Protein Isoforms , Protein Kinase C/metabolism , Protein Kinase C-alpha/drug effects , Protein Transport , Reverse Transcriptase Polymerase Chain Reaction/methods , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...